In a significant move for the neurotechnology sector, OpenAI has officially joined the seed funding round for Merge Labs, a startup focused on brain-computer interface (BCI) technology. This investment, revealed on January 15, 2026, aligns with CEO Sam Altman“s existing personal stake in the company, which is valued at $850 million.
Merge Labs aims to develop non-invasive methods that integrate gene therapy with ultrasound technology, facilitating a connection between human cognition and artificial intelligence systems. The startup has reportedly sought $250 million in funding to reach its ambitious valuation, reflecting a growing interest in BCI applications.
The Team Behind Merge Labs
The founding team of Merge Labs is noteworthy, consisting of prominent figures in neurotechnology and entrepreneurship. With researchers such as Mikhail Shapiro, Tyson Aflalo, and Sumner Norman providing scientific credibility, and operational expertise from Alex Blania and Sandro Herbig, the team is well-equipped to tackle the complexities of BCI development.
Altman”s dual role as both a co-founder and corporate backer through OpenAI raises intriguing questions about the strategic synergies between the two entities. OpenAI has expressed intentions to collaborate with Merge Labs on developing “scientific foundation models and other frontier tools,” which indicates a commitment to enhancing BCI capabilities with advanced AI infrastructure.
Non-Invasive BCI: A Game Changer
Unlike Neuralink, which necessitates surgical implantation of electrodes, Merge Labs is focusing on a less invasive route. By leveraging gene therapy and ultrasound technologies, the company aims to create a viable alternative that avoids the need for invasive procedures. This approach could significantly broaden the market potential, expanding applications beyond medical rehabilitation into areas such as productivity, gaming, and enterprise solutions.
For OpenAI, the implications of this investment are substantial. A successful BCI could establish a direct neural interface to ChatGPT and future AI models, potentially enabling users to communicate their thoughts directly. Altman emphasized the transformative nature of this technology, stating, “Each time people gain a more direct way to express intent, technology becomes more powerful and more useful.” This perspective underlines the importance of controlling brain-AI interfaces in shaping the future of computing.
Outlook for Merge Labs
The timing of the seed round suggests that Merge Labs is still several years away from launching commercial products. However, with OpenAI”s robust AI infrastructure and Altman”s expertise in fundraising, the company is well-positioned to navigate the challenges ahead in this ambitious and uncertain frontier of technology.
